INTRODUCTION AND AIMS:
Tacrolimus is a main maintenance immunosuppressant in kidney transplantation (KT), and the level at the early period after KT is very important for the prognosis of allograft. However, the common criteria of tacrolimus trough level (TTL) are uncertain. We investigated the impact of TTL in KT recipients on the post-transplant clinical outcome. METHODS: We retrospectively investigated the patients performed KT between July 2007 and June 2016. We investigated TTLs at 1 week, 2 week, 3 week, 1 month, 3 months, 6 months and 12 months after KT. We evaluated the incidence of acute rejection and cytomegalovirus (CMV) infection, and graft survival according to the TTLs. RESULTS: A total of 429 patients who received KT during the study period were enrolled. The mean age of KTRs was 46.3 6 11.5 years and male was 55.5%. TTLs (ng/ mL) at 1 week, 2 week, 3 week, 1 month, 3 months, 6 months and 12 months after KT were 6.2 (5.0 -7.9), 7.1 (5.8 -8.6), 7.8 (6.3 -9.6), 7.6 (6.0 -9.5), 6.8 (5.5 -8.4), 6.5 (5.2 -7.8), and 5.9 (4.8 -7.1). The incidence of acute rejection within 1 year after KT was significantly higher when TTLs at 3 months was less than 4.0 ng/mL (P ¼ 0.020). On the contrary, the incidence of CMV infection after 1 year was significantly higher when TTLs at 12 months was 10 ng/mL or more (P ¼ 0.015). However, the incidence of CMV infection within 1 year was not associated with TTL within 1 year. Death-censored graft survival rate was significantly lower in KTRs with acute rejection and CMV infection (P < 0.001 and 0.008). In multivariate analysis, TTL less than 4 ng/mL at 3 months after KT was an independent risk factor for graft failure. CONCLUSIONS: Acute rejection and CMV infection are important risk factors for allograft failure. Therefore, TTL should be kept at least 4 ng/mL or more at 3 months after KT to reduce the incidence of acute rejection within 1 year after KT and below 10 ng/mL since 1 year after KT to reduce the incidence of CMV infection since 1 year after KT. 
SP753 MALIGNANCY COMPLICATIONS AFTER

INTRODUCTION AND AIMS:
Immunosuppression therapy is essential to avoid rejection after kidney transplantation. The chronic use of this drugs increases the risk of malignancy compared to general population. Oncology complications are a main cause of recipient death. The increase the knowledge about the prevalence and risk factors could decrease the incidence and implement screening protocols for an early diagnosis. METHODS: We compared the incident of non-cutaneous cancers after 10 years of follow-up in three cohorts of kidney transplantations: Group A non-induction antibodies therapy, Group B received thymoglobulin and Group C received antiCD25. All patients received steroids, calcineurin inhibitors (tacrolimus vs cyclosporine) and mycophenolate vs azathioprine. We performed a Kaplan Meier survival curves freedom of neoplasm between the three different groups. We analysed risk factors associated with the development of neoplasm. RESULTS: Of the 474 kidney transplantations, 9% (43) had a non-cutaneous neoplasm after 10 years of follow up. The neoplasms were: 9 kidney-urinary tract malignancies, 9 gynecologic, 5 prostate, 5 haematological, 3 gastrointestinal, 3 lung, 2 otorhinolaryngology, 2 thyroids, 2 neurological, 2 pancreas and 1 non differentiated. We shown in Table 1 the characteristics of the patients in the Group A, B and C.
The Graphic 1 shown the survival free-neoplasm in the three groups, but there isn't any difference between the groups (p>0.05).
The multivariate analysis shown that recipient age > 55 years (HR: 2.4 [CI 1.3-4.5, p¼0.006]), previous hemodialysis as renal replacement therapy (HR: 1.9 [CI 0.96-3.7, p¼0.06]) and previous neoplasm (HR: 4.1 [CI 1.8-9.3, p¼0.001]) were the main factors to develop a neoplasm after kidney transplantation. 33 patients died after 10 years of the follow up, the main causes of deaths were cardiovascular (48.5%) and neoplasm (36.4%) causes. CONCLUSIONS: The main non-cutaneous neoplasm were related with urinary tract, gynecologic and haematological. The age older than 55 years old, previous hemodialysis renal replacement therapy and previous neoplasm were the factors related with a develop of a neoplasm after kidney transplantation. We didn't find any relationship with immunosuppression induction therapy. Oncology cause was the second cause of death in our cohort. The introduction of a neoplasm screening programme after kidney transplantation could decrease the incidence of tumor and increase recipient survival.
SP754 TREATMENT WITH GRAZOPREVIR/ELBASVIR FOR RENAL TRANSPLANT RECIPIENTS WITH CHRONIC HEPATITIS C VIRUS INFEKTION AND IMPAIRED ALLOGRAFT FUNCTION
Ute Eisenberger INTRODUCTION AND AIMS: Direct-acing antiviral agents are highly efficient treatment options for chronic hepatitis C virus (HCV) infection after renal allograft transplantation. Treatment options for patients with impaired graft function remain limited. Therefore, we assessed the effectiveness and safety of grazoprevir/elbasvir therapy for patients with chronic HCV-infection and impaired renal allograft function. METHODS: Eleven renal allograft recipients with therapy-naïve HCV genotype (GT) 1a, 1b, or 4 were treated with the fixed-dose combination of elbasvir/grazoprevir without ribavirin for 12 weeks. All recipients exhibited impaired graft function with a glomerular filtration rate (GRF) lower than 30 ml/min/1.73 m 2 . Clinical data were retrospectively reviewed for renal and liver function parameters. Patients were closely monitored for trough levels of immunosuppressive agents, viral load, laboratory values, and potential adverse effects. RESULTS: Seven patients (64%) exhibited a rapid virologic response within 4 weeks (HCV GT1a, n ¼ 2; HCV GT1b, n ¼ 5). The other four patients exhibited a virologic response within 8 weeks (HCV GT1b, n ¼3, HCV GT 4 n ¼1). All patients exhibited a sustained virologic response at week 12 after the end of Treatment (Figure1). Clinical measures of liver function improved substantially for all patients. Adverse effects were scarce. Impaired renal allograft function and proteinuria remained stable. For most patients only moderate adjustments to tacrolimus dosage were necessary for maintaining sufficient trough levels. CONCLUSIONS: This treatment appears to be safe and effective for renal transplant recipients with impaired allograft function and is a promising treatment option for eradicating HCV infection in this patient population. 
